B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
Abnormalities in B cells play pivotal roles in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Breach in central and peripheral tolerance mechanisms generates autoreactive B cells which contribute to the pathogenesis of SLE and LN. Dysregulation of B cell transcription factors, cytokines and B cell–T cell interaction can result in aberrant B cell maturation and autoantibody production. These immunological abnormalities also lead to perturbations in circulating and infiltrating B cells in SLE and LN patients. Conventional and novel immunosuppressive medications confer differential effects on B cells which have important clinical implications. While cyclophosphamide and mycophenolate mofetil (MMF) showed comparable clinical efficacy in active LN, MMF induction was associated with earlier reduction in circulating plasmablasts and plasma cells. Accumulating evidence suggests that MMF maintenance is associated with lower risk of disease relapse than azathioprine, which may be explained by its more potent and selective suppression of B cell proliferation. Novel therapeutic approaches targeting the B cell repertoire include B cell depletion with monoclonal antibodies binding to cell surface markers, inhibition of B cell cytokines, and modulation of costimulatory signals in B cell–T cell interaction. These biologics, despite showing improvements in serological parameters and proteinuria, did not achieve primary endpoints when used as add-on therapy to standard treatments in active LN patients. Other emerging treatments such as calcineurin inhibitors, mammalian target of rapamycin inhibitors and proteasome inhibitors also show distinct inhibitory effects on the B cell repertoire. Advancement in the knowledge on B cell biology has fueled the development of new therapeutic strategies in SLE and LN. Modification in background treatments, study endpoints and selective recruitment of subjects showing aberrant B cells or its signaling pathways when designing future clinical trials may better elucidate the roles of these novel therapies for SLE and LN patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074 · cited 1×
“Results from two randomized controlled trials (RCT) (BLISS-52 and BLISS-76) showed that belimumab treatment was effective in active SLE patients, but patients with moderate to severe nephritis were excluded from these two studies [121,122].”
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011 · cited 1×
“The latest EULAR guideline 2019 suggests that rituximab is to be considered in SLE patients who have severe renal or extra-renal (mainly hematological and neuropsychiatric) disease refractory to other immunosuppressants and/or belimumab, or in patients with contraindications to other immunosuppressive drugs [111].”
BackgroundChromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683 · cited 1×
“Results from two randomized controlled trials (RCT) (BLISS-52 and BLISS-76) showed that belimumab treatment was effective in active SLE patients, but patients with moderate to severe nephritis were excluded from these two studies [121,122].”
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480 · cited 1×
“Indeed, transgenic mice overexpressing BAFF exhibited increased number of plasma cells in secondary lymphoid tissues, presence of autoantibodies, and also increased circulating immune complexes and immunoglobulin deposition in the kidneys [41].”
BackgroundHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463 · cited 1×
“The ACR guidelines also recommends that rituximab treatment in LN patients who fails to improve or worsens after 6 months of standard induction therapies, or after the patient has failed both CYC or MMF treatments [75].”
BackgroundRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461 · cited 1×
“Results from the LUNAR trial showed that rituximab as add-on therapy to standard induction treatments did not improve renal outcomes although the rituximab group showed more improvement in the levels of complement and anti-dsDNA and proteinuria [104].”
MethodMerrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409 · cited 1×
“Previous studies showed that rituximab treatment could lead to profound B cell depletion as early as 2 weeks after administration, and B cells repopulate to approximately 65% of the baseline levels after 12 months [102,103].”
BackgroundMortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174 · cited 5×
“Raised blood levels of BAFF has been observed in NZB/W F1 and MRL/lpr mice at the onset of disease [22], and treatment with soluble TACI-Ig mitigated the development of proteinuria and improved survival of NZB/W F1 mice [22].”
BackgroundInfluentialMycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
Bertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Self-citationMackay, F., & Schneider, P. (2009) · Nature Reviews Immunology · doi:10.1038/nri2572 · Cited by 930 · cited 1×
“BAFF and APRIL are key survival factors for B lymphocytes and have potent stimulatory effects on B cell proliferation and antibody production [20].”
BackgroundSequential Therapies for Proliferative Lupus Nephritis
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 818
Lau, C. M., Broughton, C., Tabor, A. S., Akira, S., Flavell, R. A., Mamula, M. J., Christensen, S. R., Shlomchik, M. J., Viglianti, G. A., Rifkin, I. R., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050630 · Cited by 812
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776 · cited 1×
“Previous studies showed that rituximab treatment could lead to profound B cell depletion as early as 2 weeks after administration, and B cells repopulate to approximately 65% of the baseline levels after 12 months [102,103].”
BackgroundChan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698 · cited 1×
“While glomerulonephritis can still develop in MRL/lpr mice which were genetically manipulated to become incapable of antibody secretion, severe nephritic lesions do not occur in MRL/lpr mice with B-cell deficiency and such observation might be related to impaired development of activated cytotoxic and helper T cells i…”
BackgroundOzaki, K., Spolski, R., Ettinger, R., Kim, H.-P., Wang, G., Qi, C.-F., Hwu, P., Shaffer, D. J., Akilesh, S., Roopenian, D. C., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5361 · Cited by 668 · cited 1×
“BXSB-Yaa lupus-prone mice showed higher circulating IL-21 and its mRNA transcripts compared with wild-type mice [52], and deletion of IL-21R would abrogate characteristic lupus phenotypes such as autoantibodies production and glomerulonephritis in these mice [53].”
BackgroundDisturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus
Odendahl, M., Jacobi, A., Hansen, A., Feist, E., Hiepe, F., Burmester, G. R., Lipsky, P. E., Radbruch, A., & Dörner, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5970 · Cited by 642 · cited 3×
“The low proliferation rates in memory B cells also make them less susceptible to conventional immunosuppressive medications which are cell-cycle dependent, and thus become more readily reactivated during disease relapse [71].”
BackgroundMycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620 · cited 2×
“Rituximab is a chimeric monoclonal antibody against CD20, which was initially developed for the treatment of B cell lymphomas [93].”
BackgroundB-cell biology and development
Pieper, K., Grimbacher, B., & Eibel, H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.046 · Cited by 615 · cited 6×
“Hematopoietic stem cells commit to the lymphoid lineage and become common lymphoid precursors (CLP) [11].”
BackgroundInfluentialTipton, C. M., Fucile, C. F., Darce, J., Chida, A., Ichikawa, T., Gregoretti, I., Schieferl, S., Hom, J., Jenks, S., Feldman, R. J., et al. (2015) · Nature Immunology · doi:10.1038/ni.3175 · Cited by 581
Evolution of Autoantibody Responses via Somatic Hypermutation Outside of Germinal Centers
William, J., Euler, C., Christensen, S., & Shlomchik, M. J. (2002) · Science · doi:10.1126/science.1073924 · Cited by 559
Boulé, M. W., Broughton, C., Mackay, F., Akira, S., Marshak-Rothstein, A., & Rifkin, I. R. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031942 · Cited by 518
Autoreactivity in Human IgG+ Memory B Cells
Tiller, T., Tsuiji, M., Yurasov, S., Velinzon, K., Nussenzweig, M. C., & Wardemann, H. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.009 · Cited by 478 · cited 1×
“Memory B cells have reduced FcγRIIb expression and thus lower reactivation threshold [72,73].”
BackgroundKayagaki, N., Yan, M., Seshasayee, D., Wang, H., Lee, W., French, D. M., Grewal, I. S., Cochran, A. G., Gordon, N. C., Yin, J., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00425-9 · Cited by 477
Condon, M. B., Ashby, D., Pepper, R. J., Cook, H. T., Levy, J. B., Griffith, M., Cairns, T. D., & Lightstone, L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202844 · Cited by 454
Hoyer, B. F., Moser, K., Hauser, A. E., Peddinghaus, A., Voigt, C., Eilat, D., Radbruch, A., Hiepe, F., & Manz, R. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040168 · Cited by 440
Petri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., Recta, V., Zhong, J., & Freimuth, W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23678 · Cited by 428 · cited 1×
“levels have been observed in patients with SLE, which correlated with anti-dsDNA autoantibody levels and SLEDAI scores [43].”
BackgroundOdegard, J. M., Marks, B. R., DiPlacido, L. D., Poholek, A. C., Kono, D. H., Dong, C., Flavell, R. A., & Craft, J. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080840 · Cited by 418
Stohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34400 · Cited by 418 · cited 2×
“Memory B cells showed a biphasic response to belimumab, with a rapid increase through week 8, possibly as a result of transient redistribution of these cells from lymphoid tissues to the circulation, then followed by a gradual decline [124].”
BackgroundLai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30485-9 · Cited by 412
Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1030 · Cited by 396
Kansal, R., Richardson, N., Neeli, I., Khawaja, S., Chamberlain, D., Ghani, M., Ghani, Q.-U.-A., Balazs, L., Beranova-Giorgianni, S., Giorgianni, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1648 · Cited by 382 · cited 1×
“The application of chimeric antigen receptor T cells (CAR-T) technology can potentially confer more profound and sustained B cell depletion, and is shown to be highly effective in a murine lupus model [118].”
BackgroundAccelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM
Boes, M., Schmidt, T., Linkemann, K., Beaudette, B. C., Marshak-Rothstein, A., & Chen, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1184 · Cited by 370
Alexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H.-M., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206016 · Cited by 368
Jacobi, A. M., Odendahl, M., Reiter, K., Bruns, A., Burmester, G. R., Radbruch, A., Valet, G., Lipsky, P. E., & Dörner, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10949 · Cited by 361 · cited 1×
“Patients with active SLE have elevated number of circulating plasma cells, which shows positive relationship with serum levels of immunoglobulin and anti-dsDNA autoantibodies and disease activity scores [71,74].”
BackgroundInfluence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Isenberg, D., Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Jayne, D., Sánchez-Guerrero, J., Wofsy, D., Yu, X., & Solomons, N. (2010) · Rheumatology · doi:10.1093/rheumatology/kep346 · Cited by 356 · cited 1×
“The management of LN is challenging because of substantial patient variability in disease course and response to treatment [3,4].”
BackgroundNickerson, K. M., Christensen, S. R., Shupe, J., Kashgarian, M., Kim, D., Elkon, K., & Shlomchik, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902592 · Cited by 347
Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study
Furie, R., Nicholls, K., Cheng, T., Houssiau, F., Burgos‐Vargas, R., Chen, S., Hillson, J. L., Meadows‐Shropshire, S., Kinaszczuk, M., & Merrill, J. T. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38260 · Cited by 341 · cited 1×
“However, active Class III or IV LN patients treated with abatacept on a background of corticosteroids and MMF showed improvements in serological markers and proteinuria but did not achieve the primary study endpoint of improving renal outcomes [136].”
BackgroundMechanisms of action of CD20 antibodies.
Boross, P., & Leusen, J. H. W. (2012) · PubMed Central · Cited by 337
Survival analysis and causes of mortality in patients with lupus nephritis
Yap, D. Y. H., Tang, C. S. O., Ma, M. K. M., Lam, M. F., & Chan, T. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs073 · Cited by 319 · cited 1×
“Kidney involvement is common among patients with SLE, and the presence of lupus nephritis (LN) significantly increased the risk of renal failure and patient mortality [1,2].”
BackgroundSelf-citationRovin, B. H., Solomons, N., Pendergraft, W. F., Dooley, M. A., Tumlin, J., Romero-Diaz, J., Lysenko, L., Navarra, S. V., Huizinga, R. B., Adzerikho, I., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.08.025 · Cited by 309
Self-citationBubier, J. A., Sproule, T. J., Foreman, O., Spolski, R., Shaffer, D. J., Morse, H. C., Leonard, W. J., & Roopenian, D. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807309106 · Cited by 306 · cited 1×
“BXSB-Yaa lupus-prone mice showed higher circulating IL-21 and its mRNA transcripts compared with wild-type mice [52], and deletion of IL-21R would abrogate characteristic lupus phenotypes such as autoantibodies production and glomerulonephritis in these mice [53].”
BackgroundRationale for interleukin-6 blockade in systemic lupus erythematosus
Tackey, E., Lipsky, P. E., & Illei, G. G. (2004) · Lupus · doi:10.1191/0961203304lu1023oa · Cited by 303 · cited 1×
“IL-6 promotes the maturation of naïve B cells into memory or plasma cells, differentiation of follicular T helper cells (TFH), formation of germinal center, and production of antibodies (including autoantibodies) [19,23].”
BackgroundSuccessful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy
Bao, H., Liu, Z.-H., Xie, H.-L., Hu, W.-X., Zhang, H.-T., & Li, L.-S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121272 · Cited by 301
Herber, D., Brown, T. P., Liang, S., Young, D. A., Collins, M., & Dunussi-Joannopoulos, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3822 · Cited by 298 · cited 1×
“Fc fusion protein reduced anti-dsDNA autoantibody titers and lymph node enlargement, and also alleviated renal and dermatological lesions [54].”
BackgroundGinzler, E. M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., & Singer, N. G. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3738 · Cited by 284 · cited 1×
“Furthermore, the inhibition of B cell growth factors in addition to standard induction therapies should also be used with caution, as one previous Phase 2/3 study on atacicept (a human recombinant fusion protein of TACI and the Fc portion of IgG1) had early discontinuation due to significant risk of hypogammaglobuline…”
MethodB cell–derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity
Arkatkar, T., Du, S. W., Jacobs, H. M., Dam, E. M., Hou, B., Buckner, J. H., Rawlings, D. J., & Jackson, S. W. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170580 · Cited by 267 · cited 1×
“In a murine SLE model, B cell-derived IL-6 could induce TFH differentiation and initiate germinal center formation [45].”
BackgroundDooley, M., Houssiau, F., Aranow, C., D’Cruz, D., Askanase, A., Roth, D., Zhong, Z., Cooper, S., Freimuth, W., & Ginzler, E. (2013) · Lupus · doi:10.1177/0961203312465781 · Cited by 265 · cited 1×
“Post hoc analysis of the pooled data from these two RCTs suggested that patients treated with belimumab showed reduced risk of renal flare [123], and therefore another RCT (BLISS-LN; NCT01639339) is underway to investigate the use of belimumab in active LN patients.”
MethodMedvedovic, J., Ebert, A., Tagoh, H., & Busslinger, M. (2011) · Advances in Immunology · doi:10.1016/b978-0-12-385991-4.00005-2 · Cited by 251 · cited 2×
“PAX5 shows dual effects on early B cell development, which include the suppression of B-lineage-inappropriate genes and activation B cell-specific genes [15].”
BackgroundDíaz-Lagares, C., Croca, S., Sangle, S., Vital, E. M., Catapano, F., Martínez-Berriotxoa, A., García-Hernández, F., Callejas-Rubio, J.-L., Rascón, J., D'Cruz, D., et al. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.009 · Cited by 246
Vital, E. M., Dass, S., Buch, M. H., Henshaw, K., Pease, C. T., Martin, M. F., Ponchel, F., Rawstron, A. C., & Emery, P. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30466 · Cited by 240
Depletion of B Cells in Murine Lupus: Efficacy and Resistance
Ahuja, A., Shupe, J., Dunn, R., Kashgarian, M., Kehry, M. R., & Shlomchik, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3351 · Cited by 239 · cited 1×
“Treatment of MRL/lpr mice with anti-CD20 monoclonal antibodies resulted in decline of anti-dsDNA autoantibodies and amelioration of renal lesions [97].”
BackgroundVariable expression of Toll-like receptor in murine innate and adaptive immune cell lines
Applequist, S. E. (2002) · International Immunology · doi:10.1093/intimm/dxf069 · Cited by 238
Clowse, M. E. B., Wallace, D. J., Furie, R. A., Petri, M. A., Pike, M. C., Leszczyński, P., Neuwelt, C. M., Hobbs, K., Keiserman, M., Duca, L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39856 · Cited by 235
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.
Finck, B. K., Chan, B., & Wofsy, D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117373 · Cited by 235 · cited 2×
“Treatment of lupus prone NZB/W F1 mice with IL-6 exacerbated glomerulonephritis [46], whilst treatment with anti-IL-6 monoclonal antibodies in NZB/W F1 mice ameliorated kidney manifestations and reduced circulating anti-dsDNA autoantibodies titers [47,48].”
BackgroundIsenberg, D. A., Petri, M., Kalunian, K., Tanaka, Y., Urowitz, M. B., Hoffman, R. W., Morgan-Cox, M., Iikuni, N., Silk, M., & Wallace, D. J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207653 · Cited by 233 · cited 1×
“The results from two Phase 3 RCTs (ILLUMINATE-1 and -2) demonstrated that tabalumab treatment did not reach the primary endpoints in active non-renal SLE patients [125,126].”
BackgroundMerrill, J. T., van Vollenhoven, R. F., Buyon, J. P., Furie, R. A., Stohl, W., Morgan-Cox, M., Dickson, C., Anderson, P. W., Lee, C., Berclaz, P.-Y., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207654 · Cited by 223 · cited 1×
“The results from two Phase 3 RCTs (ILLUMINATE-1 and -2) demonstrated that tabalumab treatment did not reach the primary endpoints in active non-renal SLE patients [125,126].”
BackgroundMok, C. C., Ying, K. Y., Yim, C. W., Siu, Y. P., Tong, K. H., To, C. H., & Ng, W. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206456 · Cited by 220
Daikh, D. I., Finck, B. K., Linsley, P. S., Hollenbaugh, D., & Wofsy, D. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3104 · Cited by 217
Herlands, R. A., Christensen, S. R., Sweet, R. A., Hershberg, U., & Shlomchik, M. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.009 · Cited by 214
Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch
Muto, A., Ochiai, K., Kimura, Y., Itoh‐Nakadai, A., Calame, K. L., Ikebe, D., Tashiro, S., & Igarashi, K. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.257 · Cited by 213 · cited 2×
“Depletion of B lymphocytes can also be achieved by targeting other B cell surface molecules such as CD19 (XmAb5871) [113] and CD22 (epratuzumab) [18,114,115], and further clinical data are required to establish their roles in SLE and LN patients.”
BackgroundAlbert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., Pullman-Mooar, S., Barnack, F., Striebich, C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209
Review: Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us
Karrar, S., & Graham, D. S. C. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40396 · Cited by 204 · cited 5×
“The development and survival of B cells which react against self-antigens are prevented by both central and peripheral tolerance mechanisms [14].”
BackgroundInfluentialCutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide
Daikh, D. I., & Wofsy, D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.2913 · Cited by 203
Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., Liao, Y., Yang, Z., Zhang, J., Chen, J., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.08.036 · Cited by 202
Liang, B., Gardner, D. B., Griswold, D. E., Bugelski, P. J., & Song, X. Y. R. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02433.x · Cited by 190 · cited 2×
“Treatment of lupus prone NZB/W F1 mice with IL-6 exacerbated glomerulonephritis [46], whilst treatment with anti-IL-6 monoclonal antibodies in NZB/W F1 mice ameliorated kidney manifestations and reduced circulating anti-dsDNA autoantibodies titers [47,48].”
BackgroundBeyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
Weidenbusch, M., Römmele, C., Schröttle, A., & Anders, H.-J. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs285 · Cited by 190
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus
Sawalha, A. H., Kaufman, K. M., Kelly, J. A., Adler, A. J., Aberle, T., Kilpatrick, J., Wakeland, E. K., Li, Q.-Z., Wandstrat, A. E., Karp, D. R., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.075424 · Cited by 189 · cited 1×
“SLE patients showed raised serum IL-21 levels, and population-based case-control association analysis demonstrated that genetic polymorphisms in the IL-21 (rs907715) and IL-21R gene (rs2221903) were associated with escalated risk of SLE in European-American patients [55,56].”
Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall’Era, M., Looney, R. J., Rovin, B., Dragone, L., & Brunetta, P. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070118 · Cited by 188
Esdaile, J. M., Abrahamowicz, M., Joseph, L., MacKenzie, T., Li, Y., & Danoff, D. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390304 · Cited by 177
B-cell-directed therapies for autoimmune disease
Dörner, T., Radbruch, A., & Burmester, G. R. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.141 · Cited by 175 · cited 3×
“Follicular B cells, after cognate interaction with T helper cells, will undergo somatic hypermutation (SHM) and class switch recombination (CSR) to enhance the affinity of immunoglobulins [11,12].”
BackgroundPathogenesis of kidney disease in systemic lupus erythematosus
Bagavant, H., & Fu, S. M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832efff1 · Cited by 173
Moroni, G., Radice, A., Giammarresi, G., Quaglini, S., Gallelli, B., Leoni, A., Vecchi, M. L., Messa, P., & Sinico, R. A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094508 · Cited by 170
Wofsy, D., Hillson, J., & Diamond, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34624 · Cited by 165 · cited 1×
“related to the potent background therapy and stringent definitions of complete renal response [137].”
BackgroundLocal Renal Autoantibody Production in Lupus Nephritis
Espéli, M., Bökers, S., Giannico, G. A., Dickinson, H. A., Bardsley, V., Fogo, A. B., & Smith, K. G. C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050515 · Cited by 165 · cited 3×
“In NZB/W F1 mice, intra-renal plasma cells showed comparable number and immunoglobulin secretion as the plasma cells residing in the bone marrow, and the degree of intra-renal plasma cell infiltration also correlated with anti-dsDNA autoantibodies titers [68].”
BackgroundInfluentialJackson, S. W., Scharping, N. E., Kolhatkar, N. S., Khim, S., Schwartz, M. A., Li, Q.-Z., Hudkins, K. L., Alpers, C. E., Liggitt, D., & Rawlings, D. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400098 · Cited by 165 · cited 1×
“TLR-9 signaling in B lymphocytes is also essential for generation of autoantibodies against DNA in mice and enhances the differentiation of autoantibody-producing B cells and plasma cells in human [64,65].”
BackgroundMerrill, J. T., Shanahan, W. R., Scheinberg, M. A., KALUNIAN, K. C., Wofsy, D., & Martin, R. S. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213032 · Cited by 163 · cited 1×
“In this regard, data from a phase 3 randomized, double-blind, placebo-controlled trial suggested that blisibimod did not meet its SRI-6 endpoint but there was significantly higher proportion of patients in the treatment arm achieved partial renal response and corticosteroids taper [129].”
MethodChan, O. T. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.3592 · Cited by 162 · cited 1×
“While glomerulonephritis can still develop in MRL/lpr mice which were genetically manipulated to become incapable of antibody secretion, severe nephritic lesions do not occur in MRL/lpr mice with B-cell deficiency and such observation might be related to impaired development of activated cytotoxic and helper T cells i…”
BackgroundThe role of B cells in lupus pathogenesis
Nashi, E. P., Wang, Y., & Diamond, B. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.10.011 · Cited by 160 · cited 1×
“Increased BCR-mediated signaling can also lower the activation threshold of peripheral B lymphocytes and promote cellular phenotypes characteristic of SLE [29].”
BackgroundB cell alterations during BAFF inhibition with belimumab in SLE
Ramsköld, D., Parodis, I., Lakshmikanth, T., Sippl, N., Khademi, M., Chen, Y., Zickert, A., Mikeš, J., Achour, A., Amara, K., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.035 · Cited by 158 · cited 1×
“One prospective cohort study showed that belimumab treatment was associated with early reduction of both naïve and autoimmunity-associated B cells (CD11c + CD21-) at 3 months, but with little impact on class-switched memory B cells and plasma cells over a follow-up duration of 3 years [120].”
BackgroundCalcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help
Heidt, S., Roelen, D. L., Eijsink, C., Eikmans, M., van Kooten, C., Claas, F. H. J., & Mulder, A. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04051.x · Cited by 158
Pepper, R. J., Griffith, M. E., Kirwan, C., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp336 · Cited by 157
Meffre, E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06347.x · Cited by 155 · cited 1×
“Impaired BCR signaling in B cells will also lead to failure to trigger apoptosis of early B cells which recognize self-antigens [14,25].”
BackgroundItoh‐Nakadai, A., Hikota, R., Muto, A., Kometani, K., Watanabe‐Matsui, M., Sato, Y., Kobayashi, M., Nakamura, A., Miura, Y., Yano, Y., et al. (2014) · Nature Immunology · doi:10.1038/ni.3024 · Cited by 149 · cited 1×
“broad complex-tramtrack-bric a brac and Cap’n’collar homology 1 (BACH2), with broad complex-tramtrack-bric a brac and Cap’n’collar homology 2 (BACH1) as an auxiliary, suppress ‘myeloid genes’ in pre-pro-B cells by binding to their regulatory regions to promote development of B lymphocytes [16].”
BackgroundKitani, A., HARA, M., HIROSE, T., Harigai, M., SUZUKI, K., Kawakami, M., AWAGUCHI, Y. K., HIDAK, T., Kawagoe, A., & Nakamura, H. (1992) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1992.tb03042.x · Cited by 148 · cited 2×
“Treatment with polyclonal anti-IL-6 or anti-IL-6 receptor monoclonal antibodies could inhibit IL-6 binding and suppressed total IgG and IgG anti-ssDNA antibody secretion in lupus B cells [44].”
BackgroundDing, B. B., Bi, E., Chen, H., Yu, J. J., & Ye, B. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201678 · Cited by 144 · cited 1×
“In this context, IL-21 works synergistically with CD40L to induce differentiation of naïve and memory B cells into antibody-producing plasma cells [24].”
BackgroundInterleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.
Ryffel, B., Car, B., Gunn, H., Roman, D., HIESTAND, P. C., & Mihatsch, M. J. (1994) · PubMed · Cited by 144
Abnormalities of B cell subsets in patients with systemic lupus erythematosus
Dörner, T., Jacobi, A. M., Lee, J., & Lipsky, P. E. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.06.009 · Cited by 143 · cited 2×
“Memory B cells have reduced FcγRIIb expression and thus lower reactivation threshold [72,73].”
BackgroundSchiffer, L. E., Sinha, J., Wang, X., Huang, W., von Gonsdorff, G., Schiffer, M., Madaio, M. P., & Davidson, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.489 · Cited by 140
Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus
Malkiel, S., Barlev, A. N., Atisha-Fregoso, Y., Suurmond, J., & Diamond, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00427 · Cited by 139 · cited 1×
“Long-lived plasma cells mostly migrate back to the bone marrow and are responsible for antibody production, although a small proportion will remain in peripheral tissues [13].”
BackgroundWallace, D. J., Strand, V., Merrill, J. T., Popa, S., Spindler, A. J., Eimon, A., Petri, M., Smolen, J. S., Wajdula, J. S., Christensen, J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209668 · Cited by 139 · cited 1×
“While anti-IL-6 treatment was effective in murine LN [47,48], in a phase 2 RCT anti-IL-6 treatment (PF-04236921) did not achieve the primary efficacy endpoint in patients with non-renal SLE and the higher dose (200 mg) cohort was discontinued due to safety issues [138].”
BackgroundWallace, D. J., Gordon, C., Strand, V., Hobbs, K., Petri, M., KALUNIAN, K. C., Houssiau, F., Tak, P. P., Isenberg, D. A., Kelley, L., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/ket129 · Cited by 132 · cited 1×
“Depletion of B lymphocytes can also be achieved by targeting other B cell surface molecules such as CD19 (XmAb5871) [113] and CD22 (epratuzumab) [18,114,115], and further clinical data are required to establish their roles in SLE and LN patients.”
BackgroundYusof, M. Y. M., Shaw, D. S., El-Sherbiny, Y. M., Dunn, E. J., Rawstron, A. C., Emery, P., & Vital, E. M. J. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211191 · Cited by 129 · cited 1×
“Lower pre-treatment plasmablasts were predictive of complete B cell depletion, and B cell depletion at 6 weeks increased the odds of major clinical response [105].”
BackgroundA polymorphism within IL21R confers risk for systemic lupus erythematosus
Webb, R., Merrill, J. T., Kelly, J. A., Sestak, A., Kaufman, K. M., Langefeld, C. D., Ziegler, J., Kimberly, R. P., Edberg, J. C., Ramsey‐Goldman, R., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24658 · Cited by 122 · cited 1×
“SLE patients showed raised serum IL-21 levels, and population-based case-control association analysis demonstrated that genetic polymorphisms in the IL-21 (rs907715) and IL-21R gene (rs2221903) were associated with escalated risk of SLE in European-American patients [55,56].”
B cell autophagy mediates TLR7-dependent autoimmunity and inflammation
Weindel, C. G., Richey, L. J., Bolland, S., Mehta, A. J., Kearney, J. F., & Huber, B. T. (2015) · Autophagy · doi:10.1080/15548627.2015.1052206 · Cited by 119 · cited 1×
“TLR-7 is expressed on different B cell subpopulations and a previous study showed that autophagy in B cells was a trigger for TLR-7-dependent autoantibody production [58,59].”
BackgroundMechanisms and functions for the duration of intercellular contacts made by lymphocytes
Davis, D. M. (2009) · Nature reviews. Immunology · doi:10.1038/nri2602 · Cited by 119 · cited 1×
“, shorted interaction time in the germinal center) results in inadequate anergic signals to autoreactive B cells and hence enhancing their survival [27,28].”
BackgroundCooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation
Huang, C., Geng, H., Boss, I., Wang, L., & Melnick, A. (2014) · Blood · doi:10.1182/blood-2013-07-518605 · Cited by 114 · cited 1×
“BACH2 expression is also critical in determining the fate of B cells during germinal center reaction and can interact with BCL-6 and repress lymphocyte-induced maturation protein-1 (BLIMP-1) transcription to prevent premature plasma cell differentiation [17].”
BackgroundThe role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside
Yap, D. Y. H., & Lai, K. N. (2013) · Nephrology · doi:10.1111/nep.12047 · Cited by 114 · cited 15×
“IL-21 is a cytokine produced by activated T helper cells (especially Th2, Th17, and TFH cells), and exerts strong driving effects on plasma cell proliferation and differentiation as well as immunoglobulin production [19].”
BackgroundInfluentialSelf-citationLupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated
Wu, C., Fu, Q., Guo, Q., Chen, S., Goswami, S., Sun, S., Li, T., Cao, X., Chu, F., Chen, Z., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215039 · Cited by 109 · cited 1×
“Another recent study reported that pathogenic memory B cells isolated from treatment-naïve SLE patients showed increased mTORC1 activation, and the proliferation of these memory B cells can be significantly suppressed by RAPA treatment in vitro [147].”
BackgroundCytokines in systemic lupus erythematosus: far beyond Th1/Th2 dualism lupus: cytokine profiles
Guimarães, P. M., Scavuzzi, B. M., Stadtlober, N. P., Franchi Santos, L. F. D. R., Lozovoy, M. A. B., Iriyoda, T. M. V., Costa, N. T., Reiche, E. M. V., Maes, M., Dichi, I., et al. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.53 · Cited by 106
Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells
Lorenzetti, R., Janowska, I., Smulski, C. R., Frede, N., Henneberger, N., Walter, L. I., Schleyer, M.-T., Hüppe, J. M., Staniek, J., Salzer, U., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.016 · Cited by 105 · cited 1×
“In vitro studies showed that abatacept treatment would decrease CD80/CD86 expression and impair memory formation in human B lymphocytes [130].”
BackgroundBekar, K. W., Owen, T., Dunn, R., Ichikawa, T., Wang, W., Wang, R., Barnard, J., Brady, S., Nevarez, S., Goldman, B. I., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27515 · Cited by 100 · cited 1×
“Also, administration of anti-CD20 monoclonal antibodies in NZB/W F1 mice could delay the onset of disease and retard progression of glomerulonephritis [98].”
BackgroundThe Calcineurin Inhibitor Tacrolimus Specifically Suppresses Human T Follicular Helper Cells
Wallin, E. F., Hill, D. L., Linterman, M. A., & Wood, K. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01184 · Cited by 98
Clinical applications of anti-CD20 antibodies
Gopal, A. K., & Press, O. W. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90164-6 · Cited by 97 · cited 1×
“Anti-CD20 monoclonal antibody is an established treatment for B cell malignancy and has also been used in various autoimmune conditions [93,94].”
BackgroundToll-like receptors in lupus nephritis
Devarapu, S. K., & Anders, H. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0436-2 · Cited by 92 · cited 1×
“In this context, TLR-7 and TLR-9 are potent inducers of Type I interferon response and show more pathogenic relevance in SLE and LN [57].”
BackgroundCapolunghi, F., Rosado, M. M., Cascioli, S., Girolami, E., Bordasco, S., Vivarelli, M., Ruggiero, B., Cortis, E., Insalaco, A., Fantò, N., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq226 · Cited by 92 · cited 1×
“TLR-9 signaling in B lymphocytes is also essential for generation of autoantibodies against DNA in mice and enhances the differentiation of autoantibody-producing B cells and plasma cells in human [64,65].”
BackgroundDNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation
Wanner, N., Vornweg, J., Combes, A. N., Wilson, S. B., Plappert, J., Rafflenbeul, G., Puelles, V. G., Rahman, R., Liwinski, T., Lindner, S., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018070736 · Cited by 90
Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?
Esdaile, J. M., Joseph, L., Abrahamowicz, M., Li, Y., Danoff, D. S., & Clarke, A. E. (1996) · PubMed · Cited by 88
Fassbinder, T., Saunders, U., Mickholz, E., Jung, E., Becker, H., Schlüter, B., & Jacobi, A. M. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0603-8 · Cited by 85 · cited 3×
“Interestingly, MMF induction was associated with earlier reduction of circulating plasmablasts and plasma cells compared with CYC [83].”
BackgroundResultInfluentialYung, S., & Chan, T. M. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.09.002 · Cited by 83
Self-citationChauhan, S. K., Singh, V. V., Rai, R., Rai, M., & Rai, G. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9887-0 · Cited by 83 · cited 1×
“TLR-9 mRNA expression was also increased in PBMCs isolated from SLE patients and correlated with severity of LN and anti-DNA antibody titers [66].”
BackgroundΝάκου, Μ., Papadimitraki, E. D., Fanouriakis, A., Bertsias, G. K., Choulaki, C., Goulidaki, N., Sidiropoulos, P. I., & Boumpas, D. T. (2013) · PubMed · Cited by 82
Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice
Lui, S. L., Tsang, R., Chan, K. W., Zhang, F., Tam, S., Yung, S., & Chan, T. M. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn216 · Cited by 79 · cited 1×
“Furthermore, treatment of NZB/W F1 mice with RAPA could prevent development of nephritis and alleviate established nephritis, which was also accompanied by reduction in intra-renal B cell infiltration [148,149].”
BackgroundSelf-citationEickenberg, S., Mickholz, E., Jung, E., Nofer, J., Pavenstädt, H., & Jacobi, A. M. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3835 · Cited by 72 · cited 2×
“The authors also showed that MMF could profoundly suppress the proliferation of B cells from healthy individuals in vitro, but there was no comparison with AZA, and no information on lupus B cells [90].”
ResultLongterm Data on Sirolimus Treatment in Patients with Lupus Nephritis
Yap, D. Y. H., Tang, C. S.-O., Chan, G. C. W., Kwan, L. P. Y., Ma, M. K. M., Mok, M. M. Y., & Chan, T. M. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.180507 · Cited by 71
Self-citationRapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 mice
Lui, S., Yung, P. S., Tsang, R., Zhang, F., Chan, K., Tam, S., & Chan, T. M. (2008) · Lupus · doi:10.1177/0961203307088289 · Cited by 69 · cited 1×
“Furthermore, treatment of NZB/W F1 mice with RAPA could prevent development of nephritis and alleviate established nephritis, which was also accompanied by reduction in intra-renal B cell infiltration [148,149].”
BackgroundSelf-citationSekine, H., Watanabe, H., & Gilkeson, G. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3913 · Cited by 64
RNA sensing by conventional dendritic cells is central to the development of lupus nephritis
Celhar, T., Hopkins, R., Thornhill, S. I., Magalhães, R., Hwang, S., Lee, H.-Y., Yasuga, H., Jones, L. A., Casco, J., Lee, B. T. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507052112 · Cited by 62 · cited 1×
“TLR-7 is expressed on different B cell subpopulations and a previous study showed that autophagy in B cells was a trigger for TLR-7-dependent autoantibody production [58,59].”
BackgroundLongterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years
Yap, D. Y. H., Tang, C. S.-O., Ma, M. K. M., Mok, M. M. Y., Chan, G. C. W., Kwan, L. P. Y., & Chan, T. M. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.170226 · Cited by 59
Self-citationTraitanon, O., Mathew, J. M., Monica, G. L., Xu, L., Mas, V. R., & Gallon, L. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129658 · Cited by 56 · cited 1×
“One in vitro study showed that RAPA treatment could effectively inhibit human memory B cells proliferation and plasma cell differentiation [140].”
BackgroundAbatacept: A Review of its Use in the Management of Rheumatoid Arthritis
Keating, G. (2013) · Drugs · doi:10.1007/s40265-013-0080-9 · Cited by 54 · cited 1×
“Abatacept is currently approved for the treatment of rheumatoid arthritis and juvenile inflammatory arthritis [134].”
BackgroundZhang, H., Liu, Z., Huang, L., Hou, J., Zhou, M., Huang, X., Hu, W., & Liu, Z. (2017) · Lupus · doi:10.1177/0961203316686703 · Cited by 49 · cited 1×
“patients who were refractory to standard induction treatments [116,117].”
BackgroundChen, D. R., & Cohen, P. L. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.7 · Cited by 48 · cited 1×
“CD20 is a cell surface marker expressed on different B cell subpopulations, and therefore anti-CD20 treatment can lead to profound depletion of B lymphocytes which usually last for at least 6 months [95].”
BackgroundProliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience
Yap, D. Y. H., Maggie, K. M., TANG, C. S., & Chan, T. M. (2012) · Nephrology · doi:10.1111/j.1440-1797.2012.01646.x · Cited by 47
Self-citationMemory B Cells and Response to Abatacept in Rheumatoid Arthritis
Gazeau, P., Alegria, G. C., Devauchelle‐Pensec, V., Jamin, C., Lemerle, J., Bendaoud, B., Brooks, W. H., Saraux, A., Cornec, D., & Renaudineau, Y. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8603-x · Cited by 43 · cited 1×
“Previous studies in RA patients demonstrated that treatment with abatacept was associated with selective reduction of memory B cells, and higher basal memory B cells counts were predictive of good treatment response [135].”
ResultEffect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro.
Röllinghoff, M., Schrader, J. W., & Wagner, H. (1973) · PubMed Central · Cited by 39
Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus
Luo, J. D., Niu, X., Liu, H., Zhang, M., Chen, M., & Deng, S. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.05.241 · Cited by 34
T/B‐cell interactions are more transient in response to weak stimuli in SLE‐prone mice
Sinai, P., Dozmorov, I. M., Song, R., Schwartzberg, P. L., Wakeland, E. K., & Wülfing, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444602 · Cited by 23 · cited 1×
“, shorted interaction time in the germinal center) results in inadequate anergic signals to autoreactive B cells and hence enhancing their survival [27,28].”
BackgroundTACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression
Arkatkar, T., Jacobs, H. M., Du, S. W., Li, Q., Hudkins, K. L., Alpers, C. E., Rawlings, D. J., & Jackson, S. W. (2018) · Kidney International · doi:10.1016/j.kint.2018.03.012 · Cited by 22 · cited 1×
“Deletion of TACI receptor in transgenic mice overexpressing BAFF inhibited immune activation, diminished immunoglobulins production and conferred long-term protection from progressive glomerulonephritis for up to 12 months in these mice [42].”
BackgroundZhao, L., Jiang, Z., Jiang, Y., Ma, N., Wang, K., & Zhang, Y. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-1958-8 · Cited by 20 · cited 1×
“Other investigators have reported that CYC or MMF induction in active SLE patients was associated with different T cell subset profiles but not the B cell subpopulations after 4 weeks of treatment [84].”
Background
Metadata
- Authors
- Yap, D. Y. H., & Chan, T. M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-12-10
- Volume
- 20
- Issue
- 24
- Pages
- 6231
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2994924932
- Cited by
- 192
- References
- 137
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.